Rubicon Research bets on India’s CNS market with Arinna Lifesciences buyout

Rubicon Research has entered India’s domestic central nervous system (CNS) formulations market with the acquisition of a controlling stake in Arinna Lifesciences for Rs 175.9 crore, the company said on Wednesday.

The Mumbai‑based drugmaker said it will acquire 85 percent equity in Arinna Lifesciences Ltd., valuing the CNS‑focused company at an enterprise value of Rs 200 crore on a cash‑ and debt‑free basis.

The transaction is expected to close within 30 days, subject to customary conditions. Arinna founder Vivek Seth will retain a 15 percent stake and continue as managing director, ensuring continuity in operations.

Arinna operates primarily in chronic CNS therapies and has built a portfolio of over 60 brands, reaching more than 4,000 prescribers across India through a well‑established sales and distribution network. For the nine months ended December 31, 2025, the company reported provisional revenue of Rs 56.7 crore and EBITDA of Rs 9.5 crore.

For Rubicon, the acquisition marks a strategic shift toward building a stronger presence in India, at a time when most of its growth has come from regulated overseas markets, particularly the US. The company said the CNS segment has long been a core focus area, and Arinna provides a ready platform to bring its differentiated products closer to Indian patients.

“The past decade has demonstrated the effectiveness of Rubicon’s playbook of R&D innovation, execution rigor and impeccable compliance standards,” CEO Parag Sancheti said in a statement. He pointed out that the company’s US revenues grew more than 32 times between FY15 and FY25, driven by a focus on differentiated formulations and strong regulatory compliance.

“With Arinna, we now have a launchpad to deploy this playbook in the Indian domestic formulations market,” Sancheti said, adding that strategic M&A has been a key part of Rubicon’s expansion strategy in recent years.

Rubicon has previously used acquisitions to enter new segments, including US branded specialty products in 2024 and nasal drug development in 2020. Management believes Arinna’s established field presence and prescriber relationships will help accelerate launches in specialty CNS products and drug‑device combinations over time.

Founded in 1999, Rubicon Research has evolved from a contract development services provider into an integrated pharmaceutical company with capabilities spanning R&D, manufacturing and commercialisation. The company operates globally inspected manufacturing facilities in India regulated by agencies such as the US FDA, UK MHRA and Australian TGA, and employs more than 200 scientists across R&D centres in Mumbai and Toronto.